148436-63-9

Usage

Uses

Used in Pharmaceutical Industry:
AH 13205 is used as a neuroprotective agent for its ability to shield nerve cells from damage or degeneration. This property makes it a valuable compound in the development of treatments for neurological disorders and conditions where neuroprotection is crucial.
Used in Research Applications:
In addition to its potential therapeutic uses, AH 13205 is also utilized as a research tool in the field of neuroscience. As a selective prostanoid EP2-receptor agonist, it can help scientists better understand the mechanisms of action and signaling pathways related to this receptor, which may lead to the discovery of new therapeutic strategies for various neurological conditions.

InChI:InChI=1/C24H36O4/c1-2-3-6-10-22(25)19-14-12-18(13-15-19)20-16-17-23(26)21(20)9-7-4-5-8-11-24(27)28/h12-15,20-22,25H,2-11,16-17H2,1H3,(H,27,28)/t20-,21-,22?/m1/s1

Upstream product

• 60176-77-4 (1S,4R)-4-hydroxy-2-cyclopentenyl acetate 
• 693-25-4 n-pentylmagnesium bromide 
• 1122-91-4 4-bromo-benzaldehyde 
• 836643-56-2 [1-(4-bromo-phenyl)-hexyloxy]-tert-butyl-dimethyl-silane 
• 836643-54-0 4-(4-(1-(t-butyldimethylsilyloxy)hexyl)phenyl)-2-cyclopenten-1-ol 
• 836643-55-1 Acetic acid (1S,4S)-4-{4-[1-(tert-butyl-dimethyl-silanyloxy)-hexyl]-phenyl}-cyclopent-2-enyl ester 
• 836643-58-4 3-(4-(1-(t-butyldimethylsilyloxy)hexyl)phenyl)-2-(7-(hydroxy)heptyl)cyclopentan-1-ol 
• 836643-57-3 3-(4-(1-(t-butyldimethylsilyloxy)hexyl)phenyl)-2-(7-(4-(methoxy)benzyloxy)heptyl)cyclopentan-1-ol 
• 879098-92-7 (Z)-7-{(1R,2S)-2-[4-(1-Benzyloxy-hexyl)-phenyl]-5-oxo-cyclopentyl}-hept-5-enoic acid 
• 909528-65-0 C₂₅H₃₈O₄ 
• 879098-65-4 Acetic acid (1R,4S)-4-(1-butoxy-2-iodo-ethoxy)-cyclopent-2-enyl ester 
• 879098-69-8 (3aR,4S,6aS)-4-[4-(1-Benzyloxy-hexyl)-phenyl]-hexahydro-cyclopenta[b]furan-2-one 
• 879098-91-6 (3aR,4S,6aS)-4-[4-(1-Benzyloxy-hexyl)-phenyl]-hexahydro-cyclopenta[b]furan-2-ol 
• 879098-89-2 (3aR,4S,5R,6aS)-4-[4-(1-Benzyloxy-hexyl)-phenyl]-5-hydroxy-hexahydro-cyclopenta[b]furan-2-one 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS

Compounds having a structure are disclosed herein. Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.

THERAPEUTIC COMPOUNDS

Compounds having a structure are disclosed herein (Formula I). Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.

Cobalt(diamine)-catalyzed cross-coupling reaction of alkyl halides with arylmagnesium reagents: Stereoselective constructions of arylated asymmetric carbons and application to total synthesis of AH13205

A cobalt-diamine complex catalyzes the cross-coupling reactions of primary and secondary alkyl halides with aryl Grignard reagents. It is confirmed that oxidative addition of alkyl halide to cobalt proceeds via a radical process. Optically pure Ueno-Stork halo acetals undergo diastereoselective cross-coupling reactions, the products of which are transformed into optically active THF derivatives. A sequential radical cyclization/arylation reaction under cobalt catalysis provides extremely short access to a synthetic prostaglandin AH13205.

EP2 RECEPTOR AGONISTS

A compound selected from Formula (iv) or Formula (iii); (iv) (1R,2S)-2[4-1(S)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid [RSS] or (iii) (1R,2S)-2[4-1(R)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid [RSR] or a salt, solvate, chemically protected form or prodrug thereof, and its use in treating conditions alleviated by agonism of an EP2 receptor.

New reagent system for attaining high regio- and stereoselectivities in allylic displacement of 4-cyclopentene-1,3-diol monoacetate with aryl- and alkenylmagnesium bromides

(Chemical Equation Presented) Low regioselectivity of RMgBr (R = aryl, alkenyl) in the CuCN-catalyzed reaction with 4-cyclopentene-1,3-diol monoacetate is improved by addition of LiCl or MgCl2 to a similar extent as previously obtained with RMg